Symbols

LMAT

Lemaitre Vascular·NASDAQ

--(--)

LMAT fundamentals

LMAT Q4 2025 Earnings

Lemaitre Vascular (LMAT) released its earnings on Feb 25, 2026: revenue was 64.45M (YoY +15.48%), beat estimates; EPS was 0.68 (YoY +38.78%), beat estimates.

Revenue / YoY

64.45M

+15.48%

EPS / YoY

0.68

+38.78%

Report date

Feb 25, 2026

LMAT Earnings Call Summary for Q4,2025

Revenue Growth: 16% Q4 and 14% annual organic growth, driven by grafts, valvulotomes, and international expansion.
Gross Margin Expansion: 240 bps improvement to 71.7% in Q4, guided to 72.1% in 2026.
EPS Guidance: $2.91 for 2026, up 22% from 2025.
M&A Focus: $15M-$150M targets in open vascular and cardiac surgery.
Artegraft Success: 2025 sales of $4M, 2026 target of $10M, with revised TAM of $30M.
Operational Efficiency: 12% sales growth vs. 21% operating income growth in 2026.

Earnings

EPS

Revenue

Revenue & Expenses

LMAT has released its 2025 Q4 earnings report, with revenue of 64.45M, reflecting a YoY change of 15.68%, and net profit of 15.58M, showing a YoY change of 39.32%. The Sankey diagram below clearly presents LMAT's revenue sources and cost distribution.

Key Indicators

Lemaitre Vascular (LMAT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Lemaitre Vascular (LMAT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Lemaitre Vascular (LMAT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Lemaitre Vascular (LMAT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown